ABT Abbott Laboratories

$ABT This pumped at today's opening. The guess is that institutional buyers appreciate the spinoff while retails do not. It should go back up by today's closing when more institutional buyers jump in, as usual.

$ABT Abbott Shares Down 3.2% Premarket After Co Cuts 2026 Sales Growth View, Plans to Spin off Nutrition Business

$ABT great recovery today. Will continue to be a solid long term hold for us on into 2027 & 2028. Let's enjoy collecting the dividend in the meantime.

$ABT Rothschild & Co Redburn moved Abbott to Buy on Friday, lifting its target to 127 from 119 (per Benzinga, via MarketBeat). That is about 30 percent upside from Friday's close near 97.50. What stands out is how far the tape and the Street have drifted apart. The stock is down about 22 percent this year and still sits below its 50-day average. Meanwhile 21 analysts rate it a Buy, with an average target of 119.80. The validator is the Q3 print on Oct 21: consensus looks for adjusted EPS of 1.43 against 1.30 a year ago, and the company guides 5.45 to 5.60 for fiscal 2026. Tracking this into the Oct 21 print.

$ABT Didn't listen to the call yesterday. Just wondering how their ablation catheters are selling.

$ABT Q3 sales came in at 13.01 billion dollars, up 14.5%. Adjusted EPS was 1.42 dollars, basically in line. Diagnostics is where the headline gets loud. Reported growth was 46.7% to 3.31 billion dollars, but comparable growth was 6.4%. The Exact Sciences deal closed in March, so most of that jump is consolidation. The new Cancer Diagnostics line did 968 million dollars and grew 13.8% on a comparable basis. Medical Devices were steadier, up 6.9% reported and 7.8% comparable to 5.83 billion dollars. GAAP EPS fell to 0.53 dollars from 0.94 a year ago. Full-year adjusted EPS guide was tightened to 5.50 to 5.55 dollars, midpoint unchanged.

$ABT loving our price action & stabilization after earnings. We have established solid support in the low $102 range, & are well positioned to continue to grind higher between now & year-end. Still cannot rule out the potential for $120+ by year-end? Look forward to collecting the next dividend on 11/16 in the meantime.

$ABT: the Connoly suit alleges Abbott failed to warn a Libre 2 could read normal while glucose was actually elevated. She says she relied on those readings for a day before ICU care for DKA. Nothing to claim. Open Class Actions.

$ABT staying in the green, holding steady, & doing exactly what a quality large cap should do on a day like today when all of the major indexes are red. Very optimistic about earnings for us next week. Wishing a great weekend to all in the meantime!

$ABT breaks the support of 98 and drifts lower towards ER, hope ER number will reverse the downwards trend

$ABT: captioned as a class action, Connoly pleads only individual Louisiana product claims, with no Rule 23 class definition. Attorneys expect Libre cases to proceed individually, not as one class. Nothing to claim. Open Class Actions.

From Bloomberg, on Abbott Laboratories: “Abbott Plans to Spin Off Its Nutrition Business (ABT US)”. The company is a Below Average 1 on the Quality Score, #47 of 91 in its industry. $ABT

$ABT Heard from sales rep that they are having billing problems with their CardioMems product . 6 percent of sales . Time to dump this POS

$ABT | ABBOTT LABORATORIES Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $1.42 vs. $1.42 est. 🟠 ◆ Revenue: $13.01B vs. $12.99B est. ✅ ◆ Net Income: $920M (-44.1% YoY) ◆ Operating Income: $1.358B (-34.0% YoY) ◆ Operating Expenses: $11.655B (+25.2% YoY) ◆ R&D Expense: $920M (+20.1% YoY) Segment Performance: ◆ Medical Devices: $5.826B (+6.9% YoY) ◆ Diagnostics: $3.305B (+46.7% YoY) ◆ Nutrition: $2.262B (-82.6% YoY) ◆ Established Pharma: $1.614B (+11.2% YoY) Key Metrics: ◆ Legal settlements of approximately $670M related to Gill case and NEC claims were included in Q3 specified items totaling $1.557B after-tax. ◆ Diabetes Care sales grew 6.2% reported to $2.185B; continuous glucose monitor sales grew 7.3% reported, 7.7% comparable. ◆ Quarterly dividend declared at $0.63 per share, payable Nov. 16, 2026; Abbott has raised its dividend for 54 consecutive years. Forward Guidance: ◆ FY 2026 comparable sales growth: approximately 6.0% ◆ FY 2026 adjusted diluted EPS: $5.50 to $5.55 (range tightened, midpoint reaffirmed) ◆ Q4 2026 adjusted diluted EPS: $1.62 to $1.67

$ABT Abbott, the medical device, diagnostics and nutrition company, plans to spin off its Nutrition unit (Similac, Ensure), about $8.5B of annual sales, or ~17% of the ~$50.5B total, leaving Abbott ~$42B. Abbott was valued near $178.45B at $102.45 (16:00 ET, Oct. 20, 2026). Holders would get Nutrition shares in an intended tax-free distribution, with the combined dividend expected to equal Abbott's; one-time charges are not yet quantified. Expected by end-2027, subject to regulatory approvals, an effective Form 10 and final board approval; not assured.

$ABT 🤝 Abbott Laboratories intends to separate its global Nutrition business into an independent publicly traded company through a tax-free distribution to shareholders, expected to be completed by the end of 2027, to unlock distinct growth and value-creation strategies. Actionable market event

$ABT: have a Libre injury claim? Attorneys say preserve the sensor, glucose trace and ER records. The Connoly DKA suit is still at complaint stage, no class certified and nothing to claim. Open Class Actions.

$ABT $HOOD Is Starlink Mobile an outright carrier threat or a useful partner for telecom operators? The answer could matter as much as the technology itself. 💭

$ABT reports Wednesday before the open, consensus at 1.42 dollars EPS on 12.97 billion dollars in revenue, up 14.1% YoY. Diagnostics is carrying the growth in the models, 3.29 billion dollars, up 45.9%, and U.S. diagnostics is seen at 1.85 billion, up 108.3%. International diagnostics is only modeled up 5.7%. Nutrition is at 2.21 billion, up 2.7%, diabetes care at 2.20 billion, up 6.8%. Pretty different mix than the slow, balanced Abbott print people are used to.

$ABT $ABBV ABT was a great stock prior to 2013 and then it split giving biggest drug (Humira) to new company Abbvie. Ever since then, ABT has not been that good while Abbvie has been GREAT. 1 year return: ABT ..... -22% ABBV ...... +23% 10 year return: ABT ...... 142% ABBV ..... 349% Shame on Miles White to mess up a great company as Abbott, Mr. Abbott is turning is his grave.